Aldonist50 mg

Aldonist is a selective aldosterone (mineralocorticoid) receptor antagonist with the following evidence-based indications:

Established/FDA-approved uses

• Post-myocardial infarction heart failure: to improve survival of stable adult patients with symptomatic heart failure with reduced left ventricular ejection fraction (LVEF) after an acute myocardial infarction, used together with standard therapy including beta-blockers.
• Chronic heart failure (NYHA class II) with reduced ejection fraction: to reduce the risk of hospitalization for heart failure and cardiovascular death in adult patients with mild (NYHA class II) symptoms and left ventricular systolic dysfunction, added to standard therapy.
• Hypertension: to lower blood pressure, alone or in combination with other antihypertensive agents. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

Aldonist is not indicated as a substitute for beta-blockers, ACE inhibitors/ARBs, or other guideline-directed heart failure therapies; it is used as an add-on agent within a broader treatment regimen, not as monotherapy for heart failure.

Each film-coated tablet of Eplerenone typically contains Eplerenone 25 mg or 50 mg as the active pharmaceutical ingredient, along with standard pharmaceutical excipients. Please check the product label/pack insert of the specific brand for the exact strength and excipients available.

Aldonist is a selective aldosterone receptor antagonist (a type of potassium-sparing agent) used in the management of heart failure and hypertension. It works by blocking the binding of aldosterone to mineralocorticoid receptors in the kidney, heart, and blood vessels.

Compared with the older, non-selective mineralocorticoid receptor antagonist spironolactone, Aldonist has much lower affinity for androgen and progesterone receptors, which is why it is associated with a lower incidence of hormonal side effects such as gynecomastia and menstrual irregularities. It is taken orally, usually once daily, as part of a broader heart failure or hypertension treatment regimen.

Aldonist belongs to the therapeutic class of selective aldosterone receptor antagonists (mineralocorticoid receptor antagonists), a subclass of potassium-sparing diuretics/cardiorenal agents. It is used alongside, not as a replacement for, other heart failure therapies such as ACE inhibitors, ARBs, beta-blockers, and diuretics, or alongside other antihypertensive agent classes.

Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a hormone involved in the regulation of blood pressure and sodium/potassium balance. By blocking aldosterone's effects, Eplerenone:

• Reduces sodium reabsorption and decreases potassium excretion in the distal nephron, producing a mild diuretic and potassium-sparing effect.
• Reduces aldosterone-mediated pathological cardiac and vascular remodeling and fibrosis, which is thought to underlie its mortality benefit in heart failure.

Eplerenone has significantly lower binding affinity for androgen, progesterone, and glucocorticoid receptors compared with spironolactone, accounting for its more favorable hormonal side-effect profile.

Pharmacokinetics: Eplerenone is well absorbed orally (not affected significantly by food), extensively metabolized in the liver primarily via CYP3A4, and eliminated mainly through metabolism with subsequent renal and fecal excretion of metabolites. Its elimination half-life is approximately 4-6 hours, which is why drug interactions affecting CYP3A4, and renal/hepatic impairment, significantly influence its safety (see Interactions and Contraindications).

Aldonist tablets should be swallowed whole with a glass of water, with or without food, at approximately the same time each day. Do not stop or change the dose of Aldonist without consulting a physician, even if you feel well, since the cardiovascular and heart failure benefits depend on consistent long-term use.

Aldonist has clinically important interactions related to its metabolism (CYP3A4) and its potassium-retaining effect.

Strong CYP3A4 inhibitors

Drugs such as ketoconazole, itraconazole, clarithromycin, and ritonavir substantially increase Aldonist blood levels, increasing the risk of severe hyperkalemia. Concurrent use is contraindicated (see Contraindications).

Moderate CYP3A4 inhibitors

Erythromycin, verapamil, fluconazole, saquinavir, and similar agents moderately increase Aldonist exposure; when used together, the dose of Aldonist should not exceed 25 mg once daily (hypertension) or 25 mg every other day (heart failure per label guidance).

ACE inhibitors, ARBs, and potassium-sparing agents

Concurrent use with ACE inhibitors, angiotensin receptor blockers, other potassium-sparing diuretics, or potassium supplements increases the risk of hyperkalemia. Close monitoring of serum potassium is required; some of these combinations are contraindicated specifically in the hypertension indication (see Contraindications).

NSAIDs

Non-steroidal anti-inflammatory drugs may reduce the antihypertensive effect of Aldonist and, particularly in patients with impaired renal function or volume depletion, increase the risk of hyperkalemia and acute kidney injury.

Lithium

Concomitant use with lithium can increase serum lithium levels and the risk of lithium toxicity; monitor lithium levels frequently if this combination cannot be avoided.

Always inform your physician of all medicines, supplements, and salt substitutes (which often contain potassium) you are taking before starting Aldonist.

In patients treated for heart failure, the most commonly reported adverse effects of Aldonist are related to its potassium-sparing action:

• Hyperkalemia (more common than with placebo, and the most clinically significant adverse effect)
• Increased serum creatinine
• Dizziness
• Diarrhea
• Fatigue

In patients treated for hypertension, adverse effect rates are generally similar to placebo, but the following have been reported more often than with placebo:

• Gynecomastia (breast enlargement/tenderness in men) — less frequent than with spironolactone due to lower antiandrogenic activity, but still reported
• Abnormal vaginal bleeding in women

Uncommon but serious effects reported post-marketing include angioedema and hypersensitivity skin rash. Patients should seek prompt medical attention for symptoms of hyperkalemia (muscle weakness, irregular heartbeat, tingling) or signs of an allergic reaction while taking Aldonist.

Pregnancy: Human data on the use of Aldonist during pregnancy are limited. Animal reproduction studies have not shown teratogenic effects at exposures many times the human dose. Because adequate, well-controlled studies in pregnant women are lacking, Aldonist should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether Aldonist is present in human breast milk; animal data suggest it may be present in milk. Because of the potential for adverse effects in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Aldonist, taking into account the importance of the drug to the mother; discuss this decision with a physician.

Hyperkalemia

The most important risk associated with Aldonist is hyperkalemia, which can cause serious, potentially fatal cardiac arrhythmias. Risk is increased in patients with reduced renal function, proteinuria/diabetes, or those taking ACE inhibitors, ARBs, or NSAIDs concurrently. Serum potassium and renal function should be checked before starting Aldonist, within the first week, at one month, and periodically thereafter, especially after any dose increase.

Renal impairment

Aldonist is contraindicated in severe renal impairment and requires cautious use with dose limits and close monitoring in moderate impairment (see Contraindications and Dosage and Administration).

Hepatic impairment

Use with caution in moderate hepatic impairment due to increased drug exposure; Aldonist has not been studied in severe hepatic impairment.

Elderly patients

Elderly patients often have reduced renal function and are at higher risk of hyperkalemia while on Aldonist; more frequent potassium monitoring is prudent.

Avoid potassium supplementation

Potassium supplements and salt substitutes containing potassium should generally be avoided while taking Aldonist unless specifically directed by a physician, due to the risk of hyperkalemia.

Aldonist should be taken exactly as prescribed and should not be stopped abruptly or shared with others without medical advice.

No cases of significant human overdose with Aldonist have been well characterized, but the most likely manifestations of overdose are hypotension (low blood pressure) or hyperkalemia (high potassium, which can cause dangerous heart rhythm disturbances).

If overdose of Aldonist is suspected, seek immediate emergency medical attention or contact a poison control center right away. There is no specific antidote; treatment is supportive. If hyperkalemia develops, standard measures to lower serum potassium may be required in a hospital setting, and if hypotension occurs, supportive care (such as intravenous fluids) may be needed. Aldonist is not expected to be removed effectively by hemodialysis due to its protein binding, so management should focus on supportive care and correction of electrolyte abnormalities under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: Contraindicated in severe impairment (CrCl ≤30 mL/min); requires dose limitation and close potassium monitoring in moderate impairment (see Dosage and Administration).

Hepatic impairment: No adjustment needed in mild impairment; use with caution and closer monitoring in moderate impairment; not studied in severe impairment.

Elderly: No dosage adjustment required based on age alone, but elderly patients often have reduced renal function and should be monitored more closely for hyperkalemia while taking Aldonist.

Pediatric patients: Safety and effectiveness of Aldonist in children have not been established; a controlled trial in pediatric hypertension did not demonstrate effective blood pressure lowering in children 4 to 16 years of age.

Gender-related counseling point: Unlike spironolactone, Aldonist has minimal antiandrogenic and progestogenic activity, so it is associated with a lower incidence of gynecomastia and menstrual disturbances; this is a useful counseling point but does not change monitoring requirements.

Pregnant and breastfeeding women: See Pregnancy and Lactation section.

Aldonist is generally used long-term/chronically for heart failure (post-MI and chronic NYHA class II) and hypertension, as part of an ongoing treatment regimen directed by a physician. It is not intended for short-course or as-needed use. Treatment duration and continued need should be reassessed periodically by the prescribing physician, along with regular monitoring of serum potassium and renal function.

Eplerenone is classified as a selective aldosterone receptor antagonist (mineralocorticoid receptor antagonist), a subclass of potassium-sparing diuretic/cardiorenal agents; it is pharmacologically distinct from thiazide and loop diuretics, ACE inhibitors, ARBs, and beta-blockers, although often used in combination with these agents.

Eplerenone selectively blocks the binding of aldosterone at mineralocorticoid receptors in the kidney, heart, and vasculature. This reduces sodium retention and potassium excretion in the distal nephron, and attenuates aldosterone-driven cardiac and vascular fibrosis/remodeling, which is believed to underlie the improved survival seen with Eplerenone in heart failure. Its low affinity for androgen and progesterone receptors distinguishes it from older mineralocorticoid receptor antagonists.

The safety and effectiveness of Aldonist for heart failure or hypertension in pediatric patients have not been established. A controlled clinical trial evaluating Aldonist for hypertension in children aged 4 to 16 years did not demonstrate a significant blood-pressure-lowering effect compared with placebo. Aldonist should not be used in children outside of specialist guidance and clinical trial settings.